Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
2.
Zhonghua Wai Ke Za Zhi ; 56(9): 693-700, 2018 Sep 01.
Article in Chinese | MEDLINE | ID: mdl-30157576

ABSTRACT

Objective: To investigate the influential factors for failure of enhanced recovery after surgery(ERAS) from hepatectomy for hepatocellular carcinoma(HCC) patients and then to establish a risk prediction model. Methods: The relevant clinical data of 180 patients with HCC undergoing hepatectomy at Department of Hepatic Surgery, Affiliated Provincial Hospital, Anhui Medical University from January 2016 to June 2017 were analyzed retrospectively.There were 149 male patients and 31 female patients aging of (56.5±11.0)years(from 33 to 84 years old). The factors affecting postoperative failure of ERAS of HCC patients were identified by univariate and multivariate analyses, and then, all the obtained factors and their statistical values were used to establish the risk prediction model. Results: A total of 23 patients failed in the ERAS protocol(12.8%). The preoperative total bilirubin (TBIL), alanine aminotransferase(ALT) and amount of intraoperative bleeding were independent risk factors for failure of ERAS from hepatectomy(all P<0.05). The obtained risk prediction model was presented as follows: risk coefficient(R)=0.114×(TBIL)+ 0.082×(ALT)+ 0.008×(amount of intraoperative bleeding). At the cut of value of R=7.90, the area under the ROC curve of this model for predicting failure of ERAS was 0.866(95%CI: 0.788-0.945, P<0.01), with the sensitivity and specificity of 69.6% and 91.1%, respectively.External validation results indicated that the scoring system had good differential ability(area under the ROC curve=0.889, 95%CI: 0.811-0.967, P<0.01). Conclusions: Higher level of preoperative TBIL(>21 µmol/L) and ALT(>50 U/L) and the larger amount of intraoperative bleeding (more than 400 ml) are independent risk factors for failure of ERAS inpatients undergoing hepatectomy for HCC and the established prediction model may have certain value for risk assessment.


Subject(s)
Carcinoma, Hepatocellular , Hepatectomy , Liver Neoplasms , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/surgery , Female , Humans , Liver Neoplasms/surgery , Male , Middle Aged , ROC Curve , Retrospective Studies , Risk Factors
3.
J Int Med Res ; 38(4): 1413-27, 2010.
Article in English | MEDLINE | ID: mdl-20926014

ABSTRACT

This study was designed to investigate the in vivo growth inhibitory effects of celecoxib, a cyclo-oxygenase-2 inhibitor, and fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on the hepatocellular carcinoma (HCC) cell line, BEL-7402. Athymic nude mice implanted with BEL-7402 cells were given celecoxib and fluvastatin, either alone or in combination, and the effect of treatment on tumour growth was evaluated after 6 weeks. The combination of celecoxib and fluvastatin enhanced inhibition of tumour growth, induction of apoptosis, inhibition of tumour cell proliferation, and inhibition of tumour angiogenesis compared with either treatment alone. The combination of celecoxib and fluvastatin also increased levels of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1), decreased levels of p-Akt, myeloid cell leukaemia-1 (Mcl-1) and survivin protein, but had no effect on Akt protein levels in tumours. These results suggest that celecoxib combined with fluvastatin would be more efficacious for the treatment of HCC than either treatment alone and this combination of therapy warrants further research.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/pathology , Fatty Acids, Monounsaturated/therapeutic use , Indoles/therapeutic use , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Pyrazoles/therapeutic use , Sulfonamides/therapeutic use , Animals , Apoptosis/drug effects , Blotting, Western , Carcinoma, Hepatocellular/blood supply , Carcinoma, Hepatocellular/enzymology , Celecoxib , Cell Line, Tumor , Cell Proliferation/drug effects , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Fatty Acids, Monounsaturated/pharmacology , Fluvastatin , Humans , Indoles/pharmacology , Inhibitor of Apoptosis Proteins/metabolism , Liver Neoplasms/blood supply , Liver Neoplasms/enzymology , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Microvessels/drug effects , Microvessels/pathology , Myeloid Cell Leukemia Sequence 1 Protein , Neovascularization, Pathologic/drug therapy , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Pyrazoles/pharmacology , Repressor Proteins/metabolism , Sulfonamides/pharmacology , Survivin , Vascular Endothelial Growth Factor A/metabolism , Xenograft Model Antitumor Assays
4.
J Int Med Res ; 37(2): 417-25, 2009.
Article in English | MEDLINE | ID: mdl-19383236

ABSTRACT

An experimental rat hepatocellular carcinoma (HCC) model was established using diethylnitrosamine and N-nitrosomorpholine to induce carcinogenesis in Sprague-Dawley rats. During hepatocarcinogenesis, seven rats were sacrificed at 0, 4, 8, 12 and 16 weeks and 10 rats were sacrificed at 20 weeks. The levels of hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) protein and mRNA were examined by immunohistochemistry, Western blot and semi-quantitative reverse transcriptase-polymerase chain reaction at different stages in the rat HCC model. Twenty weeks after induction of hepatocarcinogenesis, the expression of HIF-1alpha and VEGF protein and mRNA significantly increased compared with week 0. Microvessel density (MVD) increased considerably once liver cancer developed. There was a significant positive correlation between MVD and both HIF-1alpha and VEGF, and between HIF-1alpha and VEGF levels. These results suggest that HIF-1alpha and VEGF play important roles in tumour occurrence and development during rat hepatocarcinogenesis, possibly through promoting tumour angiogenesis.


Subject(s)
Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Liver Neoplasms, Experimental/blood supply , Liver Neoplasms, Experimental/metabolism , Microvessels/pathology , Vascular Endothelial Growth Factor A/metabolism , Animals , Antigens, CD34/metabolism , Disease Models, Animal , Gene Expression Regulation, Neoplastic , Hepatocytes/metabolism , Hepatocytes/pathology , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Liver Neoplasms, Experimental/genetics , Rats , Rats, Sprague-Dawley , Vascular Endothelial Growth Factor A/genetics
5.
Water Sci Technol ; 59(5): 1037-41, 2009.
Article in English | MEDLINE | ID: mdl-19273904

ABSTRACT

A continuous experiment was carried out to study the performance of anaerobic ammonium oxidation (anammox), a novel and low cost nitrogen removal treatment process with an energy-saving characteristic. A complete mixing reactor was used with polyvinyl alcohol (PVA) gel as the carrier. In particular, performances of nitrogen removal and attachment characteristics of anammox bacteria on the PVA carrier surface were investigated. The results indicted that high concentration of anammox bacteria, up to 27,000 mg/L-carrier, had attached on the PVA carrier surface. A high nitrogen removal rate of up to 5.5 kg/m(3)-reactor/d was obtained during this continuous experiment. Furthermore, it was also confirmed that there was no generation of N(2)O gas in the anammox reaction.


Subject(s)
Polyvinyl Alcohol/chemistry , Quaternary Ammonium Compounds/chemistry , Quaternary Ammonium Compounds/metabolism , Anaerobiosis , Gels/chemistry , Nitric Oxide/chemistry , Nitrogen/isolation & purification , Oxidation-Reduction , Water
SELECTION OF CITATIONS
SEARCH DETAIL